Skip to main content
Caplight Logo









Melodia Therapeutics AG

Melodia Therapeutics AG

Private
BaselHealthcare & Life Scienceshttps://www.melodiatx.com/

Last Round

Series A

Sep 2, 2025

Company Overview

Melodia Therapeutics AG is a biotechnology company focused on developing oral therapies that target neutrophil-driven inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryclinical-stage biotechdrug developmentDPP1 inhibitorCathepsin C inhibitorinflammatory diseaseclinical trialsdrug licensingsmall-molecule therapyanti-granulocyte therapybiotech startuppharma pipelineCOPD treatmentvasculitis research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Melodia Therapeutics AG Comparables

Compare Melodia Therapeutics AG with similar companies based on industry and business-model similarity.

Melodia Therapeutics AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Insmed Incorporated
75%
Chiesi Farmaceutici S.p.A.
74%
Haisco Pharmaceutical Group
74%

Melodia Therapeutics AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 2, 2025
SeedJun 1, 2024

Key People

Founding team and executive leadership

Jonathan Talbot

Chief Executive Officer

Executive Team

Melodia Therapeutics AG Investors

Notable investors and investment history

Melodia Therapeutics AG investors
InvestorRounds
Forty51 VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 130% MoM, reaching 3.5K.

  • Mar 6, 2026

    Monthly visitors grew 2199% MoM, reaching 1.5K.

Melodia Therapeutics AG Filings

Explore SEC and related filing metadata, where available.

Melodia Therapeutics AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Melodia Therapeutics AG's valuation, stock price, and market status.

Is Melodia Therapeutics AG a public or private company?

Melodia Therapeutics AG is a private company.

What is the current stock price of Melodia Therapeutics AG?

Melodia Therapeutics AG is a private company with no public stock price. No recent secondary market data is available.

How much is Melodia Therapeutics AG worth (valuation)?

Valuation information for Melodia Therapeutics AG is not publicly available.

Can I buy Melodia Therapeutics AG stock?

Melodia Therapeutics AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Melodia Therapeutics AG's last funding round?

Melodia Therapeutics AG's most recent funding round was Series A on September 2, 2025.

Who are the main investors in Melodia Therapeutics AG?

Key investors in Melodia Therapeutics AG include Forty51 Ventures.

Will Melodia Therapeutics AG IPO soon?

No public IPO plans have been announced for Melodia Therapeutics AG.

How can I track Melodia Therapeutics AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Melodia Therapeutics AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range1
Year Founded2023
Last FundingSep 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?